Archives
-
Amikacin (BAY416651) in CREC Resistance Workflows
2026-09-08
Use Amikacin (BAY416651) as a controlled phenotypic probe alongside genotyping, plasmid analysis, and transfer assays in carbapenem-resistant Enterobacterales research. This workflow emphasizes reproducible stock preparation, genotype–phenotype interpretation, and troubleshooting rather than treating one susceptibility result as proof of mechanism.
-
AZ505: Practical SMYD2 Inhibition Workflows
2026-09-08
Learn how to deploy AZ505 as a substrate-competitive SMYD2 inhibitor across biochemical, cellular, and cisplatin-induced renal fibrosis workflows. The guide pairs product-performance data with assay controls, translational context, and troubleshooting for epigenetic regulation research and cancer biology research.
-
Carbapenemase Gene Transmission in CREC: Guangdong Study
2026-09-07
A 2025 multicenter study analyzed carbapenem-resistant Enterobacter cloacae from eight teaching hospitals in Guangdong, China, linking carbapenemase-gene localization with plasmid transfer, mobile genetic elements, and strain relatedness. The findings identify blaNDM-1 as the dominant transferable determinant and provide a practical framework for distinguishing horizontal plasmid dissemination from clonal spread in hospital surveillance.
-
Bifendate (DDB): A Multiomics Guide to Liver Injury
2026-09-07
Bifendate (DDB) is a hepatoprotection agent whose effects span lipid handling, autophagy flux, and inflammatory networks. This article translates multiomics findings into practical assay decisions while distinguishing mechanistic evidence from translational hypotheses.
-
Dimetridazole: From Mechanism to Translational Strategy
2026-09-05
Dimetridazole is gaining renewed value as a mechanistically informed research tool for antimicrobial-resistance studies. This article connects its membrane, fatty-acid, quorum-sensing, biofilm, and analytical properties to practical validation strategies, while clarifying the limits between in vitro evidence, infection-model research, and clinical translation.
-
Shh–Fgf10–Fgfr2 in Species-Specific Penile Development
2026-09-04
Wang and Zheng show that species-specific differences in prepuce timing and urethral groove formation are associated with differential Shh, Fgf10, and Fgfr2 expression in guinea pigs and mice. By combining comparative gene-expression analysis with genital-tubercle culture experiments, the study provides a mechanistic framework for interpreting mammalian penile morphogenesis and for designing pathway-perturbation studies.
-
Valemetostat: Assay Logic for EZH2 Lymphoma Research
2026-09-04
Valemetostat and DS-3201 provide a precise framework for studying EZH2-driven lymphoma biology. This article connects biochemical selectivity, phenotype-first assay design, and lessons from a metabolic disease study without overstating cross-domain evidence.
-
Tofacitinib in RA Macrophage Research Workflows
2026-09-03
Tofacitinib (CP-690550) gives researchers a practical way to connect JAK/STAT pathway inhibition with inflammatory and mitochondrial readouts in GM-CSF-driven rheumatoid arthritis macrophage models. This guide translates recent findings into dose-ranging, assay-selection, and troubleshooting workflows while separating reported evidence from optimization starting points.
-
Octyl-α-ketoglutarate for HIF-1α Studies
2026-09-03
Octyl-α-ketoglutarate is a cell-permeable prolyl hydroxylase substrate for testing whether intracellular α-KG availability can restore HIF-1α turnover in metabolically rewired cells. This article provides a practical workflow for connecting IDH perturbation, TCA cycle dysfunction research, oxygen sensing, and metabolic phenotypes with better controls and troubleshooting.
-
PMSF for Reliable Protein Extraction and Western Blotting
2026-09-02
PMSF provides targeted, irreversible serine protease control during tissue and cell lysis, helping preserve fragile protein signals for Western blotting. This practical guide connects PMSF-enabled sample preparation with placenta biology, apoptosis research, and troubleshooting strategies that prevent protease-related data loss.
-
ATRA Sensitizes Ovarian Cancer to PARP Inhibition
2026-09-02
This study identifies all-trans retinoic acid (ATRA) as a clinically relevant strategy for reducing cisplatin-associated PARP inhibitor resistance in epithelial ovarian cancer. Its experiments connect treatment response to suppression of NAMPT, PARP1, checkpoint kinase 1, aldehyde dehydrogenase 1A1, and intracellular NAD+, supporting a sequential cisplatin–niraparib–ATRA maintenance framework.
-
Deracoxib and Piroxicam in Canine Osteosarcoma
2026-09-01
This 2005 study compared deracoxib with piroxicam in three canine osteosarcoma cell lines and one fibroblast line, combining viability measurements with DNA-fragmentation analysis. Deracoxib produced concentration-dependent loss of osteosarcoma cell viability at lower concentrations than piroxicam while sparing fibroblasts within the tested range, but the study found no evidence that either drug caused apoptosis under its limited fragmentation-testing conditions.
-
S63845: MCL1 Inhibitor for Apoptosis Assays
2026-09-01
S63845 is a selective MCL1 inhibitor for dissecting mitochondrial apoptosis beyond simple viability measurements. This article shows how GET3-dependent MCL1 membrane targeting, cell-cycle state, and orthogonal BAX/BAK readouts can improve interpretation in hematological cancer research.
-
From E3-Ligase Mechanism to FLAG-Tagging Strategy
2026-08-31
A translational framework connecting the NEDD4L–PRMT5–AKT/mTOR metastasis mechanism with rigorous recombinant protein validation using the 3X (DYKDDDDK) Peptide and 3X FLAG peptide.
-
Hydroxyl-Radical Degradation of Dimetridazole
2026-08-31
This theoretical study maps how hydroxyl radicals transform Dimetridazole and ornidazole in water, combining reaction mechanisms, rate calculations, lifetime estimates, and toxicity prediction. Its central implication is that rapid chemical degradation does not necessarily mean immediate detoxification, because early transformation products may be more hazardous than the parent compounds.